Gene
NOTCH2
NOTCH2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (15), Actionable biomarkers (4), Trial mentions (6), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NOTCH2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 at the structurally incomplete recent edge.
NOTCH2 has 6 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 7 of 11,460 | 0.06% |
| 2022 | 0 of 8,285 | 0.00% | 7 of 13,598 | 0.05% |
| 2021 | 0 of 8,692 | 0.00% | 15 of 15,045 | 0.10% |
| 2020 | 1 of 7,640 | 0.01% | 17 of 14,459 | 0.12% |
| 2019 | 0 of 7,300 | 0.00% | 12 of 12,159 | 0.10% |
| 2018 | 0 of 6,927 | 0.00% | 13 of 11,854 | 0.11% |
| 2017 | 0 of 6,558 | 0.00% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
Assay-provider ledger (15)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, University Health Network | Not a company | Analytical validation | 1 | February 18, 2025 |
| Agilent | Reagent supplier | Analytical validation | 2 | February 18, 2025 |
| BC Cancer Research Institute (Lab#2) | Not a company | Analytical validation | 1 | February 18, 2025 |
| Integrated DNA Technologies | Reagent supplier | Analytical validation | 1 | February 18, 2025 |
| Sanofi R&D | Pharma or other | Clinical validation | 1 | June 07, 2018 |
Showing 5 of 15 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain) | MK-0752 | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain) | MK-0752 | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain) | MK-0752 | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NOTCH2 fusion | Gamma Secretase Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (6)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05529069 | Trial eligibility (AACT) |
| NCT06357676 | Trial eligibility (AACT) |
| NCT06656221 | Trial eligibility (AACT) |
| NCT02576665 | Trial eligibility (AACT) |
| NCT05861050 | Trial eligibility (AACT) |
Showing 5 of 6 trial mentions.
Target-disease associations (668)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 12q14 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Acromesomelic dysplasia, Grebe type | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Adrenal Gland Neuroblastoma | cancer or benign tumor | Cancer Gene Census |
| Alagille syndrome | cardiovascular disease | clingen |
| Alagille syndrome | cardiovascular disease | Literature (Europe PMC) |
Showing 5 of 668 associations.
Vendor sourcing (45)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense... | View ClinVar record SCV002521503.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.6079A>G (p.K2027E) alteration is located in exon 34 (coding exon 34) of the NOTCH2 gene. This alteration results from a A to G substitution at nucleoti... | View ClinVar record SCV000740745.4 |
| Baylor College of Medicine | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | PM2, PP3 | View ClinVar record SCV005911516.1 |
| Children's Hospital of Philadelphia | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV000258192.5 |
| City of Hope Medical Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutiona... | View trial NCT05861050 |
Showing 5 of 45 sourcing records.
Trial-cited literature (130)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Predictive biomarkers for immunotherapy response in extensive-stage SCLC. | Journal of cancer research and clinical oncology | 2024 | 27 |
| Distinctive field effects of smoking and lung cancer case-control status on bronchial basal cell growth and signaling. | Respiratory research | 2024 | 4 |
| Impact of genome build on RNA-seq interpretation and diagnostics. | medRxiv : the preprint server for health sciences | 2024 | 0 |
| Lung cancer immunotherapy: progress, pitfalls, and promises. | Molecular cancer | 2023 | 839 |
| Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. | Blood advances | 2023 | 41 |
Showing 5 of 130 papers.
Protein variant mentions (89)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A2018S | 1 | 2015 | PMID 25741868 |
| p.A2188T | 1 | 2015 | PMID 25741868 |
| p.A2397G | 1 | 2015 | PMID 25741868 |
| p.A2448S | 1 | 2015 | PMID 25741868 |
| p.A3S | 1 | 2015 | PMID 25741868 |
Showing 5 of 89 variants.
Literature-extracted relations (10)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Adenocarcinoma of Lung | Disease | associate |
Distinctive field effects of smoking and lung cancer case-control status on bronchial basal cell growth and signaling. | 2024 |
| Melanoma | Disease | associate |
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. | 2020 |
| Lymphoma, Large B-Cell, Diffuse | Disease | associate |
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. | 2020 |
| Alagille Syndrome | Disease | associate |
Alagille syndrome mutation update: Comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. | 2019 |
| Breast Neoplasms | Disease | associate |
Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance. | 2018 |
Showing 5 of 10 relation assertions.
Organizations publishing (195)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Dana-Farber Cancer Institute | Other | 7 | 2012 to 2020 |
| Government of the United States of America | Government | 7 | 2009 to 2023 |
| Harvard Medical School | Academic | 5 | 2015 to 2020 |
| Memorial Sloan Kettering Cancer Center | Hospital | 5 | 2015 to 2019 |
| The University of Texas System | Academic | 5 | 2014 to 2022 |
Showing 5 of 195 organizations.
Where NOTCH2 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
602 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.